Monopar Therapeutics (MNPR) Common Equity: 2016-2020
Historic Common Equity for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $17.5 million.
- Monopar Therapeutics' Common Equity rose 278.20% to $17.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.5 million, marking a year-over-year increase of 278.20%. This contributed to the annual value of $12.6 million for FY2019, which is 82.53% up from last year.
- As of Q3 2020, Monopar Therapeutics' Common Equity stood at $17.5 million, which was up 43.91% from $12.2 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Common Equity registered a high of $17.5 million during Q3 2020, and its lowest value of $2.8 million during Q4 2016.
- Its 3-year average for Common Equity is $9.2 million, with a median of $8.1 million in 2018.
- In the last 5 years, Monopar Therapeutics' Common Equity plummeted by 38.95% in 2019 and then soared by 278.20% in 2020.
- Quarterly analysis of 5 years shows Monopar Therapeutics' Common Equity stood at $2.8 million in 2016, then spiked by 239.78% to $9.6 million in 2017, then fell by 28.08% to $6.9 million in 2018, then skyrocketed by 82.53% to $12.6 million in 2019, then skyrocketed by 278.20% to $17.5 million in 2020.
- Its Common Equity was $17.5 million in Q3 2020, compared to $12.2 million in Q2 2020 and $12.4 million in Q1 2020.